Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1998;82:503-512

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Senzaki, H.
Right arrow Articles by Kass, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senzaki, H.
Right arrow Articles by Kass, D. A.
(Circulation Research. 1998;82:503-512.)
© 1998 American Heart Association, Inc.


Original Contributions

Synergistic Exacerbation of Diastolic Stiffness From Short-term Tachycardia–Induced Cardiodepression and Angiotensin II

Hideaki Senzaki, Yehezkiel A. Gluzband, Peter H. Pak, Michael T. Crow, Joseph S. Janicki, , David A. Kass

From the Division of Cardiology (H.S., P.H.P., D.A.K.), Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Md; the Laboratory of Cardiovascular Science (Y.A.G., M.T.C.), Gerontology Research Center, National Institute on Aging, Baltimore, Md; and the Department of Physiology and Pharmacology (J.S.J.), Auburn University, Auburn, Ala.

Correspondence to David A. Kass, MD, Halsted 500, Division of Cardiology, Johns Hopkins Medical Institutions, 600 N Wolfe St, Baltimore, MD 21287. E-mail dkass{at}eureka.wbme.jhu.edu

Abstract—Synergistic interaction between angiotensin II (Ang II) and evolving cardiodepression may play an important role in worsening chamber function, particularly in diastole. To test this hypothesis, Ang II was infused at 10 or 17 ng · kg-1 · min-1 in 18 conscious dogs 4 days before and during induction of subacute cardiodepression by 48-hour tachypacing. The lower dose yielded negligible systemic pressure changes. Twelve additional animals served as paced-only controls. Pressure-dimension relations were recorded, and serial endocardial biopsies were obtained to assess histological and metalloproteinase (MMP) changes. Forty-eight–hour pacing alone depressed systolic function but had little effect on diastolic stiffness. Ang II alone only modestly raised diastolic stiffness at both doses and enhanced contractility at the higher dose. These changes recovered toward baseline after a 7-day infusion. However, Ang II (at either dose) combined with 48-hour pacing markedly increased ventricular stiffness (110±26% over baseline) and end-diastolic pressure (22±1.7 mm Hg). In contrast, pacing-induced inotropic and relaxation abnormalities were not exacerbated by Ang II. Zymography revealed MMP activation (72- and 92-kD gelatinases and 52-kDa caseinase) after a 4-day Ang II infusion (at both doses), which persisted during pacing. Tachypacing initiated 24 hours after cessation of a 7-day Ang II infusion also resulted in diastolic stiffening and corresponded with MMP reactivation. Ang II also induced myocyte necrosis, inflammation, and subsequent interstitial fibrosis, but these changes correlated less with chamber mechanics. Thus, Ang II amplifies and accelerates diastolic dysfunction when combined with evolving cardiodepression. This phenomenon may also underlie Ang II influences in late-stage cardiomyopathy, when chamber distensibility declines.


Key Words: heart failure • diastole • metalloproteinase • myocardium • ventricle




This article has been cited by other articles:


Home page
Arch. Dis. Child.Home page
H Senzaki
The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases
Arch. Dis. Child., October 1, 2006; 91(10): 847 - 851.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Paolocci, B. Tavazzi, R. Biondi, Y. A. Gluzband, A. M. Amorini, C. G. Tocchetti, M. Hejazi, P. M. Caturegli, J. Kajstura, G. Lazzarino, et al.
Metalloproteinase Inhibitor Counters High-Energy Phosphate Depletion and AMP Deaminase Activity Enhancing Ventricular Diastolic Compliance in Subacute Heart Failure
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 506 - 513.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Funabiki, K. Onishi, K. Dohi, T. Koji, K. Imanaka-Yoshida, M. Ito, H. Wada, N. Isaka, T. Nobori, and T. Nakano
Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure
Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2487 - H2492.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Nishikawa, K. Yamamoto, Y. Sakata, T. Mano, J. Yoshida, T. Miwa, H. Takeda, M. Hori, and T. Masuyama
Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation
Cardiovasc Res, March 1, 2003; 57(3): 766 - 774.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. L. Brower, A. L. Chancey, S. Thanigaraj, B. B. Matsubara, and J. S. Janicki
Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity
Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H518 - H525.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
H. Senzaki, C.-H. Chen, S. Masutani, M. Taketazu, J. Kobayashi, T. Kobayashi, N. Sasaki, H. Asano, S. Kyo, and Y. Yokote
Assessment of cardiovascular dynamics by pressure-area relations in pediatric patients with congenital heart disease
J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 535 - 547.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. Shirakabe, S. Yamaguchi, Y. Tamada, G. Baniya, A. Fukui, H. Miyawaki, and H. Tomoike
Impaired distensibility of the left ventricle after stiffening of the right ventricle
J Appl Physiol, July 1, 2001; 91(1): 435 - 440.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C.-P. Cheng, T. Ukai, K. Onishi, N. Ohte, M. Suzuki, Z.-S. Zhang, H.-J. Cheng, H. Tachibana, A. Igawa, and W. C. Little
The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure
Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1853 - H1860.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Senzaki, N. Paolocci, Y. A. Gluzband, M. L. Lindsey, J. S. Janicki, M. T. Crow, and D. A. Kass
{beta}-Blockade Prevents Sustained Metalloproteinase Activation and Diastolic Stiffening Induced by Angiotensin II Combined With Evolving Cardiac Dysfunction
Circ. Res., April 14, 2000; 86(7): 807 - 815.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. D. Prabhu and G. L. Freeman
Altered LV inotropic reserve and mechanoenergetics early in the development of heart failure
Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H698 - H705.
[Abstract] [Full Text] [PDF]